Toronto Dominion Bank acquired a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 510,600 shares of the company's stock, valued at approximately $6,760,000.
Other large investors have also recently added to or reduced their stakes in the company. QRG Capital Management Inc. boosted its stake in Takeda Pharmaceutical by 16.8% during the 4th quarter. QRG Capital Management Inc. now owns 329,644 shares of the company's stock valued at $4,364,000 after acquiring an additional 47,490 shares during the last quarter. Russell Investments Group Ltd. boosted its stake in Takeda Pharmaceutical by 48.6% during the 4th quarter. Russell Investments Group Ltd. now owns 45,324 shares of the company's stock valued at $600,000 after acquiring an additional 14,831 shares during the last quarter. US Bancorp DE boosted its stake in Takeda Pharmaceutical by 21.2% during the 4th quarter. US Bancorp DE now owns 124,332 shares of the company's stock valued at $1,646,000 after acquiring an additional 21,744 shares during the last quarter. Blue Trust Inc. boosted its stake in Takeda Pharmaceutical by 27.0% during the 4th quarter. Blue Trust Inc. now owns 14,430 shares of the company's stock valued at $205,000 after acquiring an additional 3,071 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Takeda Pharmaceutical by 60.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock valued at $2,409,000 after acquiring an additional 68,200 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors.
Takeda Pharmaceutical Stock Performance
Shares of NYSE:TAK traded down $0.11 on Tuesday, reaching $14.97. 1,105,752 shares of the company's stock were exchanged, compared to its average volume of 1,935,407. The firm has a market capitalization of $47.63 billion, a price-to-earnings ratio of 37.43, a PEG ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.43. The business's 50-day moving average is $14.65 and its two-hundred day moving average is $14.07. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The firm had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. As a group, equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.
Analysts Set New Price Targets
Separately, Morgan Stanley raised shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.
Read Our Latest Report on TAK
About Takeda Pharmaceutical
(
Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
See Also
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
